重写CAR-T细胞命运：CRISPR/Cas基因编辑用于实体瘤治疗
Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.
摘要(中文译文)
尽管嵌合抗原受体T（CAR-T）细胞疗法在血液系统恶性肿瘤中取得了显著成功，但其在实体瘤中的治疗效果仍受到若干挑战的限制，包括肿瘤浸润不足、T细胞耗竭以及免疫抑制性肿瘤微环境（TME）。CRISPR/Cas是近年来发展起来的第三代基因编辑技术，具有简便高效的特点。该技术在多个领域展现出广泛的应用潜力，并已成为改进CAR-T细胞疗法的有力工具。在本综述中，我们总结了应用CRISPR/Cas基因编辑技术增强CAR-T细胞抗实体瘤活性的最新进展。我们还讨论了当前面临的关键挑战，并系统地提出了克服这些局限性的潜在策略。
Abstract
Although chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable success in hematological malignancies, its therapeutic efficacy in solid tumors remains limited by several challenges, including insufficient tumor infiltration, T cell exhaustion and the immunosuppressive tumor microenvironment (TME). CRISPR/Cas, a third-generation gene editing technology developed in recent years, is characterized by its simplicity and high efficiency. This technology has demonstrated broad application potential across multiple fields and has emerged as a powerful tool for improving CAR-T cell therapy. In this review, we summarize recent advances in the application of CRISPR/Cas gene editing technology to enhance the antitumor activity of CAR-T cells against solid tumors. We also discuss the key challenges currently faced and systematically propose potential strategies for overcoming the limitations.
如何引用
AMA
Wenjing Liu, Jiayi Gu, Chenghao Xie, Bing Du, Mingyao Liu, Jiqin Zhang. Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1910092.
APA
Wenjing Liu, Jiayi Gu, Chenghao Xie, Bing Du, Mingyao Liu, Jiqin Zhang (2026). Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1910092
GB/T 7714
Wenjing Liu, Jiayi Gu, Chenghao Xie, Bing Du, Mingyao Liu, Jiqin Zhang. Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1910092.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出